Status:
COMPLETED
Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration
Lead Sponsor:
Asklepios proresearch
Collaborating Sponsors:
Cordis US Corp.
Conditions:
Left Ventricular Dysfunction
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Evaluative pilot study for safety and feasibility with administration of autologous bone bone marrow derived mononuclear cells by endoventricular catheter into the normal border zone fo the ischemic l...
Eligibility Criteria
Inclusion
- LVEF \<40%
- PCI at latest 6 hours after infarction
- BMI \>20 kg/m² and \<30 kg/m²
Exclusion
- PCI elder than 14 days
- relevant valvular disease
- left ventricular dysfunction caused by other reasons than ischemic cardiomyopathy
- history of stroke, chronic atrial fibrillation, multivessel disease, thromboembolic event
- scheduled for CABG
- DM Type 1 \& extensive hypercholesterinemia
- pacemaker
- systemic disease
- Pregnancy
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00938847
Start Date
February 1 2006
End Date
October 1 2008
Last Update
July 14 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asklepios Klinik St. Georg, Departement of Cardiology
Hamburg, Germany, 20099